| 9 0.29 (3.33%) | 09-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.92 | 1-year : | 11.69 |
| Resists | First : | 9.35 | Second : | 10.01 |
| Pivot price | 8.76  |
|||
| Supports | First : | 8.3 | Second : | 6.9 |
| MAs | MA(5) : | 8.67 |
MA(20) : | 8.9 |
| MA(100) : | 7.8 |
MA(250) : | 6.76 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 40.3 |
D(3) : | 26.3 |
| RSI | RSI(14): 52.8 |
|||
| 52-week | High : | 10.14 | Low : | 4.5 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ACOG ] has closed below upper band by 16.6%. Bollinger Bands are 46.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 9.19 - 9.23 | 9.23 - 9.26 |
| Low: | 8.53 - 8.57 | 8.57 - 8.61 |
| Close: | 8.94 - 9 | 9 - 9.07 |
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Mon, 28 Sep 2026
Two days of buying: Alpha Cognition (ACOG) 10% owner's fund pays $8.47 and $8.5664 a share. - Stock Titan
Wed, 16 Sep 2026
Alpha Cognition (ACOG) 10% holder adds 123,918 shares near $8.40–$8.72 - Stock Titan
Wed, 09 Sep 2026
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Thu, 13 Aug 2026
Alpha Cognition Inc. (ACOG) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Thu, 13 Aug 2026
Alpha Cognition Inc. Reports Second Quarter 2026 Financial Results and Provides Operational Update - Business Wire
Thu, 06 Aug 2026
Alpha Cognition Inc. (ACOG) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 22 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 5.1 (%) |
| Held by Institutions | 56.1 (%) |
| Shares Short | 209 (K) |
| Shares Short P.Month | 204 (K) |
| EPS | -0.96 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.43 |
| Profit Margin | -137.7 % |
| Operating Margin | -127.3 % |
| Return on Assets (ttm) | -30.4 % |
| Return on Equity (ttm) | -49.6 % |
| Qtrly Rev. Growth | 267.6 % |
| Gross Profit (p.s.) | 0.63 |
| Sales Per Share | 0.7 |
| EBITDA (p.s.) | -1.22 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -31 (M) |
| Levered Free Cash Flow | -29 (M) |
| PE Ratio | -9.38 |
| PEG Ratio | 0 |
| Price to Book value | 3.7 |
| Price to Sales | 12.84 |
| Price to Cash Flow | -6.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|